AI assistant
Sending…
Bone Biologics Corp — Director's Dealing 2023
Sep 20, 2023
35440_dirs_2023-09-20_4e0fb785-7edb-4ef9-8619-95395efab53e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2023-09-18
Reporting Person: Stroever Bruce (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-09-18 | Non-Employee Stock Option | $0.64 | A | 85763 | Acquired | 2033-09-13 | Common Stock (85763) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Non-Employee Stock Option | $48.41 | 2027-08-23 | Common Stock (1229) | 1229 | Direct |
| Non-Employee Stock Option | $105.60 | 2032-01-01 | Common Stock (291) | 291 | Direct |
| Non-Employee Stock Option | $157.50 | 2031-10-26 | Common Stock (99) | 99 | Direct |
Footnotes
F1: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.
F2: This option is fully vested as of the date of this report.
More from Bone Biologics Corp
Interim / Quarterly Report
2026
May 14
Annual Report
2026
Mar 2
Director's Dealing
2026
Jan 21
Director's Dealing
2026
Jan 21
Regulatory Filings
2026
Jan 8
Interim / Quarterly Report
2025
Nov 14
Major Shareholding Notification
2025
Nov 7
Capital/Financing Update
2025
Sep 26
Regulatory Filings
2025
Sep 4
Regulatory Filings
2025
Aug 29